Sector News

Pfizer rejigs executive roster to put Albert Bourla at Read's right hand

November 13, 2017
Life sciences

Pfizer now has a chief operating officer and, potentially, a successor to CEO Ian Read. It’s Albert Bourla, who’s headed up the company’s Innovative Health unit since early 2016.

Adding a COO to the executive roster will allow Read to “spend more time focusing on the company’s long-term strategic direction, ensuring continued R&D productivity and engaging with government policy and industry leaders on key issues facing the future of the healthcare industry,” the CEO said in the statement.

It also sets up Bourla at Read’s right hand, a spot that’s auspicious for his future at the company, as the Wall Street Journal noted. Read is 64, and though he’s not ready to make an exit, he did want to set up a plan for his succession when the time comes, the newspaper reported, citing an anonymous source.

Bourla will move into the newly created slot on Jan. 1, the company said in a Monday statement. He’ll oversee R&D, sales and strategy across the company, Pfizer said. His promotion will trigger other management switches; John Young, who’s been running Pfizer’s Established Products unit, will move into Bourla’s current job, and Angela Hwang, who heads up the company’s inflammation and immunology business, will take over at Established Products.

In announcing the move, Pfizer emphasized Bourla’s recent success at driving growth in the Innovative Health business, with 9% revenue growth so far this year. Cancer med Ibrance, which Bourla handled in his previous role as president of vaccines, oncology and consumer health, has been among the company’s most successful recent launches.

By Tracy Staton

Source: Fierce Pharma

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend